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Abstract
Albendazole is a benzimidazole carbamate extensively used in oral chemotherapy against intestinal parasites, due to its
broad spectrum activity, good tolerance and low cost. However, the drug has the disadvantage of poor bioavailability due
to its very low solubility in water; as a consequence, a very active area of research focuses on the development of new
pharmaceutical formulations to increase its solubility, dissolution rate, and bioavailability. The primary objective of this
study was to prepare randomly methylated b-cyclodextrins inclusion complexes to increase albendazole dissolution rate, in
order to enhance its antiparasitic activity. This formulation therapeutic efficacy was contrasted with that of the pure drug by
treating Trichinella spiralis infected mice during the intestinal phase of the parasite cycle, on days five and six post-infection.
This protocol significantly decreased muscle larval burden measured in the parenteral stage on day 30 post-infection, when
compared with the untreated control. Thus, it could be demonstrated that the inclusion complexes improve the in vivo
therapeutic activity of albendazole.
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Introduction
Trichinellosis is a foodborne parasitic zoonosis widely distrib-
uted all over the world in most climates, except for deserts, with a
burden of approximately 10,000 people per year and a 0.2%
mortality rate. [1] Humans acquire the infection by ingestion of
undercooked meat contaminated with Trichinella spp. Muscle
encysted larvae are set free after gastric digestion and maturing
into adult worms that penetrate the mucosa of the intestine. After
fertilization, female worms release newborn larvae that dissemi-
nate throughout the host to find the striated muscle where they
encyst [1–3]. The administration of efficacious anthelmintic drugs
at the stage of intestinal invasion is remarkably important to obtain
an effectual therapy [4].
Albendazole (ABZ) is a benzimidazole carbamate widely used
for the treatment of trichinellosis [1–4]. The drug belongs to Class
II in the Biopharmaceutics Classification System. It is poorly water
soluble and highly lipophilic (log P of 2.55) and, consequently, it
can exhibit unfavourable bioavailability after oral administration,
leading to variable oral absorption [5]. In this context, several
formulation techniques have been previously investigated to
increase ABZ dissolution rate, including solid dispersion, poly-
meric microencapsulation and complexation with cyclodextrins
(CDs) [5–12].
The use of CDs as suitable pharmaceutical excipients is an
attractive alternative to prepare liquid and solid formulations to
enhance the dissolution rate and bioavailability of poorly soluble
drugs [13–15].
Accordingly, b-CD has attained pharmaceutical relevance
despite its low aqueous solubility, since chemical modifications
increase this parameter due to the loss of the crystalline solid state
[16–18]. Furthermore, Lajos Szente and Jozsef Szejtli [19],
postulated that the random substitution of any hydroxyl group
produces an interference of the stable hydrogen bond system
around the b-CD rims causing an intensive enhancement of the
aqueous solubility. Thus, several CD derivatives of pharmaceutical
interest have been developed including the hydroxypropyl
derivatives of b-CD and c-CD, the randomly methylated b-CD
(RM-b-CD), sulfobutylether b-CD, and the so-called branched
CDs such as maltosyl-b-CD [20]. Hydroxypropyl b-CD (HP-b-
CD) is much more water-soluble and more toxicologically benign
than the natural b-CD, and its most important use is for the
intravenous route.
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There is an extensive prior work on the use of CDs to improve
ABZ water solubility. Including others authors, Bassani et al., [9]
proposed a liquid formulation which included ABZ in HP-b-CD,
in a molar ratio of 1/10, which resulted in a significant increase in
the drug aqueous solubility, up to 3500 times, compared with the
native b-CD to be administered by the parenteral route.
Concerning the oral route, Diaz et al. [21], studied inclusion
complexes employing a, b, c and HP-CD to improve the solubility
behavior and ABZ dissolution rate. The complexation has been
studied by using electronic absorption spectroscopy and molecular
mechanics. In addition, Castillo et al. [7] formulated ABZ:HP-b-
CD freeze-dried inclusion complexes. They observed an important
increase of the ABZ solubility, although a supersaturation effect
was observed when drug release studies were performed in non-
sink conditions.
The role of RM-b-CDs in improving oral drug delivery and
dissolution rate is based on the dramatic rise in the aqueous
solubility of the RM-b-CDs (.500 mg/mL) (18.5 mg/mL) [22]
and the affinity for the hydrophobic molecules in comparison with
the b-CD. RM-b-CDs are absorbed moderately from the
gastrointestinal tract into the systemic circulation, enhancing the
oral bioavailability and drug permeability by making the drug
accessible at the surface of the biological barrier [13,19,23,24].
Furthermore, RM-b-CD may also inhibit P-gp function in small
intestinal epithelial cells after oral administration, resulting in an
increase in the drug activity [24]. Another important use of RM-b-
CD is to protect some molecules, such as proteins, from
gastrointestinal conditions. Sajaresh et al. proposed an interesting
oral insulin delivery system based on RM-b-CD complexed insulin
encapsulated in polymethacrylic acid (PMAA) hydrogel micropar-
ticles evaluated under invitro conditions [23].
This work aimed to modify the ABZ water solubility through
complexation with RM-b-CD. The inclusion complex and
physical mixtures were prepared and methodically characterized
using ultraviolet–visible (UV–vis) spectroscopy, X-ray diffraction,
differential scanning calorimetry, and nuclear magnetic resonance
spectroscopy (1H-13C and Rotating-Frame Overhauser Effect
Spectroscopy, ROESY) and dissolution studies. The stoichiometry
and equilibrium constants, which allow quantitative description of
the solubility behavior, were determined by phase-solubility
studies.
The antiparasitic activity of the ABZ:RM-b-CD complex was
evaluated in a murine model of trichinellosis [25,26]. ABZ and the
inclusion complex formulations were administered during the
intestinal phase of the parasite cycle, on days 5 and 6 post-
infection.
This study has been focused on providing an efficient approach
in order to develop ABZ pharmaceutical formulations for oral




ABZ (1 mg/mL aqueous solubility), b-CD, HP-b-CD, RM-b-
CD were supplied by Sigma-Aldrich Chemie GmbH (Steinheim,
Germany). All other chemicals were of analytical grade.
Methods
Solubility diagrams. Solubility diagrams were obtained
according to Higuchi and Connors [27]. Briefly, excess amounts
of ABZ (30 mg) were added to 10 mL of water containing various
concentrations (0–60 mM) of b-CD, HP-b-CD or RM-b-CD.
Samples were shaken for 72 h in an elliptical shaker at 180 rpm
and 37uC and then filtered through a 0.45 mm membrane filter
(Advantec MFS, Inc.). ABZ concentration in the filtrate was
spectrophotometrically analyzed at 291 nm (Boeco S-26 spec-
trometer, Hamburg, Germany). The phase-solubility diagrams
were obtained and the complex formation constant (Kf) were
calculated according to the equation:
S (tan a) S0 (solubility of the drug in the absence of CD).
Kf~S=S0 1-Sð Þ
Each experiment was performed in triplicate.
Preparation of inclusion complexes and physical
mixtures. The inclusion complexes were prepared by spray
Figure 1. DSC thermograms. A: ABZ (pure drug), B: RM-b-CD, C:
ABZ:RM-b-CD obtained by physical mixtures, D: ABZ:RM-b-CD obtained
by spray drying.
doi:10.1371/journal.pone.0113296.g001
Figure 2. X ray diffraction patterns. A: ABZ (pure drug), B: RM-b-CD,
C: ABZ:RM-b-CD obtained by physical mixtures, D: ABZ:RM-b-CD
obtained by spray drying.
doi:10.1371/journal.pone.0113296.g002
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drying. ABZ was dissolved in acetic acid; water and b-CD, HP-b-
CD or RM-b-CD, were added to that solution. The molar ratio
was 1:1. The resulting solutions were spray-dried in a Mini Spray
Dryer Buchi B-290 (Flawil, Switzerland) under the following
conditions: inlet temperature, 130uC; outlet temperature, 70uC;
air flow, 38 m3/h; feed, 5 mL/min; aspirator set, 100%.
Additionally, physical mixtures between ABZ and b-CD or
RM-b-CD were prepared in a mortar by mixing the drug and
carrier for 10 minutes.
Complex Characterization
Differential scanning calorimetry. Differential scanning
calorimetry (DSC) was performed on a Shimadzu TA-60 (Kyoto,
Japan) calorimeter, using 5 mg samples in crimped aluminium
pans. The instrument was calibrated with indium and zinc as
standards. Nitrogen was used as a purge gas, and an empty
aluminium pan was employed as a reference. Each sample was
scanned at a rate of 5uC/min from 25 to 350uC, under N2
atmosphere (flow rate 30 mL/min).
X-Ray Diffraction. Data collection was carried out in
transmission mode on an automated X’Pert Phillips MPD
diffractometer (Eindhoven, The Netherlands). X-ray diffraction
patterns were recorded using CuKa radiation (l= 1.540562 A˚),
40 kV voltage, 20 mA current and steps of 0.02u on the interval
2h= 10u–40u. Low peak broadening and background were assured
by using parallel beam geometry with an X-ray lens and a graphite
monochromator placed before the detector window. Data
acquisition and evaluation were performed with the Stoe Visual-
Xpow package, Version 2.75 (Germany).
ESI-MS analysis. The stoichiometry of the complex was
confirmed by mass spectrometry with high resolution. The
equipment used was a micrOTOF-Q II spectrometer, Bruker-
Daltonics (Bremen, Germany) equipped with an electrospray
ionization source (ESI). ESI-MS conditions were optimized to
improve the analysis of the complexes. The spectrometer
parameters were set as follows: ESI (negative ion mode), collision
energy: 210 eV, spray voltage 2.8 kV, nebulizer: 0.4 bar, dry
heater: 180uC, drying gas flow rate: 4.0 L/min, end plate offset: 2
500 V, set collision Cell RF: 300.0 Vpp. The spectra of the
investigated compounds were acquired in the range m/z 50–3000.
ABZ:RM-b-CD inclusion complex was dissolved in a 0.4% v/v
solution of formic acid (FA).
Figure 3. ESI-MS spectrum. A: Partial MS spectrum of ABZ:RM-b-CD obtained by spray drying dissolved in a formic acid solution. B and C: Zoom of
regions corresponding to RM-b-CD and ABZ:RM-b-CD, respectively. The masses and the number of methyl substituents are written above each peak.
doi:10.1371/journal.pone.0113296.g003
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ROESY experiments. Two-dimensional rotating-frame
Overhauser effect spectroscopy (ROESY) experiments were used
to confirm the current complexation of ABZ with RM-b-CD, as
well as to characterize their binding mode. The ABZ:RM-b-CD
complex (10 mg) was solubilized in 0.5 mL 0.1 N DCl in D2O,
and filtrated (0.45 mm Millipore membrane filter). ROESY
measurements were performed with a Bruker Avance 300
instrument (Karlsruhe, Germany) with a 5 mm probe using the
roesyph pulse sequence (Bruker) with the experimental conditions
as follows: 32 scans, acquisition time 0.222 s, pulse delay 1.92 s
and 512 data points [28]. Resonance at 4.7 ppm was used as an
internal reference due to residual solvent water (H2O and HDO).
Dissolution studies. Dissolution studies were performed in
900 mL 0.1 N HCl at 37uC, according to the U.S. Pharmacopeia
[29] Apparatus 2 (SR8 8-Flask Bath, Hanson Research, Chats-
worth, CA) with paddle rotating at 50 rpm. Samples of ABZ pure
drug, physical mixtures or spray-dried complexes equivalent to
Figure 4. ROESY spectrum. A: ABZ proton labelling, B: RM-b-CD proton labelling. C and D: Plot of two dimensional ROESY spectrum of ABZ in the
presence of RM-b-CD.
doi:10.1371/journal.pone.0113296.g004
Figure 5. Dissolution profiles. Release profiles of ABZ (raw material),
ABZ loaded in physical mixtures (b-CD and RM-b-CD), ABZ loaded in the
inclusion complexes (spray drying) (b-CD and RM-b-CD). Test condi-
tions: 0.1N HCl, 37 uC (n = 36SD).
doi:10.1371/journal.pone.0113296.g005
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100 mg of the drug were spread on the surface of the dissolution
medium and the time 0 was recorded. At appropriate time
intervals, 5 mL samples were withdrawn and filtered (pore size
0.45 mm). The amount of drug released was determined by UV
analysis, measuring the absorbance spectrophotometrically at
291 nm.
Dissolution efficiency (DE) a concept proposed by Khan and
Rookes in 1975 [30] and defined as the area under a dissolution
curve between specified time points, was calculated using the
following equation:






where y is the percentage of dissolved product at time t.
Antiparasitic activity assay in Trichinella spiralis infected
mice. Susceptible CBi+ mice, of the CBi colony from the
Animal Facilities of the Instituto de Gene´tica Experimental,
Facultad de Ciencias Me´dicas, Universidad Nacional de Rosario
(from here on, CBi-IGE stock), were used to evaluate the in vivo
effect of ABZ formulations on Trichinella spiralis muscle cyst
formation. Mice and facilities conditions were described elsewhere
[6]. Briefly, young adults were housed, separated by sex since
weaning, in polypropylene cages (32 cm624 cm610 cm) with
wood shavings for bedding, in a room with constant temperature
(2462uC), with a relative humidity of 50610% and a light-dark
illumination cycle of 12 h. Cages and bedding were changed twice
a week. Tap water and food (Cargill Laboratory Chow, pelletized)
were provided ad libitum. Adult CBi+ males (90–100 days old)
were weighed (mean weight 5463 g) and orally infected with 2
Trichinella spiralis infective muscle larvae per g of body weight.
The larvae used in the infection were recovered by artificial
digestion in a solution of 1% pepsin 1% HCl at 37uC, from the
muscles of a CBi+ mouse that had been infected 2–3 months
earlier; the infection dose for each animal was prepared by
counting individual larvae. After infection, the animals were
divided in three groups (n = 5 per group) to test the effect of the
solid systems on Trichinella spiralis infectivity: I) ABZ; II)
ABZ:RM-b-CD complex and III) infection control without
treatment. Groups I and II were treated with 50 mg ABZ per
kg of body weight on days 5 and 6 post-infection.
During the course of the experience, the animals were examined
three times a week to determine whether infection altered their
physical condition, looking for signs and symptoms of trichinel-
losis. No signs of illness, pain or distress were observed [31].
The anthelmintic activity of the novel ABZ formulation was
assessed on the chronic phase of the infection (3262 days post-
infection), by counting the number of muscle encysted parasites
(muscle parasitic burden) in the tongue of each mouse, as already
described [6]. Briefly, after euthanizing the mouse, by inhalation
of CO2, the tongue was excised, weighed and digested in 2 mL of
digestion fluid. The mixture was incubated at 37 uC overnight and
stirred periodically at moderate speed. At the end of the
incubation period, digestion was stopped by adding saline to
complete 14 mL and the larvae were allowed to decant for 1 h.
The supernatant was removed immediately and 5 mL of 10% v/v
formalin were admixed in order to inactivate and preserve intact
the structure of the larvae. Finally, all larvae on each sample were
counted under a microscope with a 40X magnification. Parasite
burden was calculated as the total number of larvae per g of
muscle tissue (PBr). The reduction percentage of PBr in the treated
animals was calculated as follows:
Mouse A PBr percentage reduction~
PBr control group meanmouse A PBr:100
PBr control group mean
All the experiments with mice were done during the first half of
the light cycle and according to animal care standards of the
institution, which complies with guidelines established by the
Institute for Laboratory Animal Resources. The protocol was
approved by the Animal Care and Use Committee of the National
University of Rosario (Permit Number: 648/2012).
The statistical significance of the differences in PBr among
groups was assessed by the non-parametric Kruskal-Wallis analysis
of variance, and Dunn’s post-test was used for comparisons
between groups. Variables expressed as percentages were studied
with the Mann-Whitney ‘‘U’’ test. Differences were considered
significant if p,0.05.
Results and Discussion
Solubility diagrams of the ABZ:CDs formulations
The complex formation constants (Kf) showed the relationship
between ABZ and the corresponding CDs (b-CD, HP-b-CD and
RM-b-CD). The phase solubility diagrams of HP-b-CD and RM-
b-CD fit an AL-type profile very well [27]. This curve indicates the
formation of soluble 1:1 type inclusion complex. The Kf value
obtained for the inclusion complex between ABZ and RM-b-CD
was 336.70 M21 suggesting a stable complex in comparison with
the Kf obtained with b-CD: 67.90 M21 and HP-b-CD:
313.16 M21. Thus, according to the solubility isotherms obtained,
ABZ improved its solubility with RM-b-CD in comparison with b-
CD and HP-b-CD.
Table 1. Efficacy of the ABZ:RM-b-CD formulation on the muscle larval load of Trichinella spiralis infected CBi+ males.
Group Relative larval load* Coefficient of variation (%) Larval load reduction percentage**
I)ABZ 5806133.4a,b 51.4 76a (65–90)
II)ABZ:RM-b-CD 435663.0b 32.4 84a (79–90)
III)Control 27126500.5a 41.3 –
Differences among groups were evaluated with the Kruskal-Wallis test, using Dunn’s post-test for comparisons between groups (Relative larval load), or by the non
parametric Mann-Whitney test (Larval load reduction percentage).
For each variable, differences between groups not sharing the same superscript are significant at the 0.001 level.
Larval load was measured in the tongue, a preferred site of encystment in mice.
*Mean 6 SEM **Median (range).
doi:10.1371/journal.pone.0113296.t001
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The better Kf value obtained for RM-b-CD supported the
selection of this derivative to formulate the inclusion complexes,
complete its characterization and evaluate in vivo its anthelmintic
activity.
Characterization of the ABZ:RM-b-CD complexes and
physical mixtures
Differential scanning calorimetry. Figure 1 shows DSC
thermograms of ABZ, RM-b-CD and the systems prepared by
physical mixtures and spray drying. The characteristic sharp
melting peak of ABZ was observed at 196.84 uC. The intensity of
the drug endothermic peak was also recorded in the physical
mixture system thermogram. The absence of the ABZ peak in the
spray dried system could be due to the formation of an inclusion
complex [32,33].
X-Ray Diffraction. The powder X-ray patterns of ABZ,
RM-b-CD and ABZ:RM-b-CD systems obtained by physical
mixtures and spray drying are shown in Figure 2. The derivative
RM-b-CD showed an amorphous structure; ABZ presented
intense and characteristic diffraction peaks at 2h 11.51; 17.85;
22.09 y 24.54. The diffraction patterns of ABZ in the physical
mixtures indicated the simple overlapping of the ABZ and RM-b-
CD diffraction peaks, indicating that the crystallinity of ABZ did
not change essentially. The lower intensity of some ABZ peaks
could be a dilution effect due to the presence of the RM-b-CD. On
the other hand, the diffraction patterns of the spray drying system
showed wider intense peaks, implying that ABZ is in an
amorphous state. XRD analyses are in substantial agreement
with DSC data. The thermal parameters of ABZ:RM-b-CD
complex could be attributed to partial complexation of the drug in
the CD cavity, confirming the amorphizing role of RM-b-CD
[34].
ESI-MS analysis. Figure 3 shows a part of the MS spectrum
of ABZ:RM-b-CD (spray dried) dissolved in FA solution. The
multiple-peaks achieved are related to each ionic species and were
due to the RM-b-CD derivatives were formed with different
number of methyl groups. Ions at m/z 1291.5, 1305.5, 1319.5,
1333.6, 1347.6, 1361.6, 1375.6, 1389.6 were according to eight
derivatives bearing from eight to fifteen methyl substituents. The
largest peaks for each degree of substitution corresponded to FA
adducts. The average degree of substitution of the RM-b-CD was
12.2 per CD molecule calculated according to its abundance ratio.
The search of the ABZ:RM-b-CD inclusion complex was
carried out in negative mode. Ions at m/z 1510.6, 1524.6, 1538.6,
1552.6, 1566.6, 1580.7, 1594.7 and 1608.7 corresponded to the
complex in a molar ratio 1:1, between ABZ (Ion at m/z 264.1) and
the RM-b-CD with eight to fifteen methyl substituents. No strong
peaks were detected above the 1608 m/z value, indicating the
formation of an ABZ:RM-b-CD complex in 1:1 and not 1:2 molar
ratio.
ROESY experiments. An unambiguous 1H NMR spectral
assignment is required to establish the inclusion mode of ABZ in
the RM-b-CD cavity. The labeling of all the signals in the 1H
NMR spectra of ABZ and RM-b-CD were carried out using the
information obtained from H–H COSY, H-C HSQC and H-C
HMBC spectra (data not shown). The structure of both molecules
is shown in Figure 4.
The changes in chemical shifts induced by direct methylation
and the effects on nuclei next to a methylated site generated
unresolved broad peaks in the 1H NMR spectrum. It could be
observed that the signals of H2 and H6 of the substituted (sub) sites
produced overlapping signals with the protons of 6-OCH3 and
H5, respectively.
Figure 4 (C and D) shows a partial contour plot of a 2D
ROESY spectrum of the inclusion complex ABZ:RM-b-CD. This
spectrum exhibited intermolecular cross peaks between the
aromatic ring protons (Figure 3 A: e, f and g) and RM-b-CD
cavity protons (H3 and H5). These data suggest that the
interactions of the aromatic ring take place in the CD cavity.
Additionally, the presence of cross peaks between the protons of
the methoxy groups of RM-b-CD and the ABZ protons a, b and f
indicate that these drug protons were in a shallow position in the
CD cavity.
Dissolution profiles. Dissolution profiles of ABZ:RM-b-
CD, ABZ:b-CD, obtained by spray drying or physical mixtures,
and non-treated ABZ were performed to determine the dissolution
rate of ABZ loaded in each system (Figure 5). The profiles
corresponding to ABZ:b-CD physical mixtures and the pure drug
showed similar results, reaching only 26% and 15% drug release
after six hours of the running assay. The ABZ:b-CD spray-dried
complex and the physical mixtures prepared with ABZ:RM-b-CD
achieved, respectively, 23% and 54% of drug release after 10 min
of the running assay.
The dissolution profiles of ABZ loaded in the RM-b-CD
inclusion complex prepared by spray drying exhibited a 100%
drug release after 10 minutes of the running assay. The dissolution
efficiency areas of ABZ:RM-b-CD physical mixtures (70.32%) and
spray dried preparations (92.78%) were 7.6 and 10 times higher
than the drug without any treatment (9.16%). These results
demonstrate, undoubtedly, the improvement of the dissolution
rate of ABZ loaded in this carrier.
In vivo study of the antiparasitc efficacy of the ABZ:RM-b-
CD complex
The spray dried inclusion complexes improved their intestinal
anthelmintic efficacy compared with that of ABZ alone. As shown
in Table 1, mice given the spray dried ABZ:RM-b-CD complex
had the lowest mean parasitic burden as well as the lowest
variance, and differed significantly from the non-treated control
group. The ABZ-treated group increased its relative variability
compared to the control mice as derived from the coefficients of
variation. In contrast, the ABZ:RM-b-CD complex-treated group
decreased its variability. These results support the notion that ABZ
low solubility affects its bioavailability and induces a heteroge-
neous therapeutic response. While statistically significant differ-
ences between the treated groups were not seen, the effect of
differences such as lower mean response and variability is
consistent with the supposition of a better performance of the
new formulation. The homogenous response observed in mice
treated with the complex may be associated to a better dissolution
rate, and potentially a better bioavailability of ABZ.
Conclusions
The physicochemical evaluation of the inclusion complexes
prepared with ABZ and RM-b-CD showed promising results. The
drug release rate was remarkably improved; achieving dissolution
efficiency areas 10 times higher than the drug alone demonstrating
that the RM-b-CD is a suitable excipient for the design of oral
dosage forms with poorly soluble compounds. Moreover, these
results were consistent with the loss of crystallinity observed by
XRD and DSC analysis. ABZ inclusion complex was also
confirmed by NMR studies. The in vivo assessment of the
complex antiparasitic effectiveness in a murine model of
trichinellosis revealed a decrease in mice muscle parasitic burden
compared with that of animals treated with the unmodified drug.
Therefore, the inclusion complex with RM-b-CD by spray drying
Cyclodextrin Derivative Complex of Albendazole. In Vivo Evaluation
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is an interesting alternative to treating parasitic intestinal
infections.
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